|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Nurix Therapeutics, Inc. (NRIX) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
47,040,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies designed to modulate cellular protein levels as a treatment approach for cancer and other diseases. Co.'s Bruton's tyrosine kinase (BTK) degrader drug candidates, NX-2127 and NX-5948, are orally available chimeric targeting molecules for the treatment of relapsed or refractory B-cell malignancies and autoimmune indications. Co.'s drug candidate from its E3 ligase inhibitor portfolio, NX-1607, is an orally bioavailable Casitas B-lineage lymphoma proto-oncogene B inhibitor for immuno-oncology indications.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
15,218 |
35,430 |
43,924 |
56,372 |
| Total Sell Value |
$172,193 |
$362,771 |
$427,193 |
$583,289 |
| Total People Sold |
3 |
3 |
3 |
4 |
| Total Sell Transactions |
5 |
10 |
16 |
32 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Beaurang Pierre |
Chief Business Officer |
• – – |
2021-02-18 |
4 |
OE |
$0.84 |
$55,275 |
D/D |
15,000 |
15,000 |
|
- |
|
| Ring Christine |
General Counsel |
• – – |
2021-02-18 |
4 |
AS |
$34.48 |
$71,750 |
D/D |
(2,000) |
0 |
|
- |
|
| Ring Christine |
General Counsel |
• – – |
2021-02-18 |
4 |
OE |
$1.86 |
$3,720 |
D/D |
2,000 |
2,000 |
|
- |
|
| Hansen Gwenn |
Chief Scientific Officer |
• – – |
2021-02-18 |
4 |
AS |
$35.81 |
$29,018 |
D/D |
(800) |
12,000 |
|
- |
|
| Hansen Gwenn |
Chief Scientific Officer |
• – – |
2021-02-18 |
4 |
OE |
$7.26 |
$5,808 |
D/D |
800 |
12,800 |
|
- |
|
| Van Houte Hans |
Chief Financial Officer |
• – – |
2021-02-18 |
4 |
AS |
$34.24 |
$481,621 |
D/D |
(13,583) |
0 |
|
- |
|
| Van Houte Hans |
Chief Financial Officer |
• – – |
2021-02-18 |
4 |
OE |
$0.84 |
$11,410 |
D/D |
13,583 |
13,583 |
|
- |
|
| Levin Mark J |
10% Owner |
– – • |
2021-02-04 |
4 |
D |
$0.00 |
$0 |
D/D |
(914,216) |
4,508,333 |
|
- |
|
| Hansen Gwenn |
Chief Scientific Officer |
• – – |
2020-11-30 |
4 |
OE |
$0.84 |
$10,080 |
D/D |
12,000 |
12,000 |
|
- |
|
| Green Jeremy |
10% Owner |
– – • |
2020-07-28 |
4 |
A |
$0.00 |
$0 |
I/I |
1,176,470 |
1,176,470 |
|
- |
|
| Wellington Biomedical Innovation Master Investors |
10% Owner |
– – • |
2020-07-28 |
4 |
A |
$0.00 |
$0 |
D/D |
784,313 |
784,313 |
|
- |
|
| Goeddel David V |
Managing Partner |
– • • |
2020-07-28 |
4 |
A |
$0.00 |
$0 |
D/D |
6,672,548 |
686,274 |
|
- |
|
| Svennilson Peter |
Managing Partner |
– – • |
2020-07-28 |
4 |
A |
$0.00 |
$0 |
D/D |
6,672,548 |
686,274 |
|
- |
|
| Tepper Robert I |
10% Owner |
– – • |
2020-07-28 |
4 |
A |
$0.00 |
$0 |
D/D |
5,422,549 |
5,422,549 |
|
- |
|
| Tjian Robert |
Director |
– • – |
2020-07-28 |
4 |
A |
$0.00 |
$0 |
I/I |
91,666 |
124,999 |
|
- |
|
| Sands Arthur T |
President, CEOOfficer |
• • – |
2020-07-23 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
600,000 |
|
- |
|
| Sands Arthur T |
President, CEOOfficer |
• • – |
2020-07-23 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
308,333 |
|
- |
|
| Svennilson Peter |
10% Owner |
– – • |
2020-07-23 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
83,333 |
|
- |
|
| Lacey David L. |
Director |
– • – |
2020-07-23 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
33,333 |
|
- |
|
| Kunkel Lori Anne |
Director |
– • – |
2020-07-23 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
54,027 |
|
- |
|
| Beaurang Pierre |
Chief Business OfficerOfficer |
• – – |
2020-07-23 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
116,666 |
|
- |
|
| Tjian Robert |
Director |
– • – |
2020-07-23 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
33,333 |
|
- |
|
| Goeddel David V |
10% Owner |
– – • |
2020-07-23 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
83,333 |
|
- |
|
173 Records found
|
|
Page 7 of 7 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
